Results 41 to 50 of about 78,708 (218)

Vaccination in emergencies. [PDF]

, 1999
Nongovernmental organisations (NGOs) are the main actors of vaccine delivery during complex humanitarian emergencies such as large population displacements.
Paquet, C
core   +2 more sources

Vaccines against malaria [PDF]

Philosophical Transactions of the Royal Society B: Biological Sciences, 2011
There is no licenced vaccine against any human parasitic disease and Plasmodium falciparum malaria, a major cause of infectious mortality, presents a great challenge to vaccine developers. This has led to the assessment of a wide variety of approaches to malaria vaccine design and development, assisted by the ...
openaire   +3 more sources

“More” Artificial mRNAs: Beyond the Art of Nature

Advanced Science, EarlyView.
Inspired by nature yet transcending it, synthetic mRNA is being redesigned beyond the canonical architecture. This review highlights emerging forms—circular, branched, and self‐amplifying mRNAs—that expand stability, persistence, and functional control, illustrating how artificial mRNA is evolving into a new medium for programmable biological ...
Yuanzhe Cui, Minami Fukui, Hirohisa Ohno, Hirohide Saito   +3 more
wiley   +1 more source

Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates

npj Vaccines
Vaccines to the Plasmodium falciparum reticulocyte binding-like protein homologue 5 (PfRH5) target the blood-stage of the parasite life cycle. PfRH5 has the potential to trigger the production of strain-transcendent antibodies and has proven its efficacy
Laty G. Thiam, Kirsty McHugh, Aboubacar Ba, Rebecca Li, Yicheng Guo, Mariama N. Pouye, Awa Cisse, Dimitra Pipini, Fatoumata Diallo, Seynabou D. Sene, Saurabh D. Patel, Alassane Thiam, Bacary D. Sadio, Alassane Mbengue, Inés Vigan-Womas, Zizhang Sheng, Lawrence Shapiro, Simon J. Draper, Amy K. Bei   +18 more
doaj   +1 more source

Malaria vaccines and their potential role in the elimination of malaria

Malaria Journal, 2008
Research on malaria vaccines is currently directed primarily towards the development of vaccines that prevent clinical malaria. Malaria elimination, now being considered seriously in some epidemiological situations, requires a different vaccine strategy,
Greenwood Brian M, Targett Geoffrey A
doaj   +1 more source

The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection

Frontiers in Immunology, 2020
The RTS,S/AS01 vaccine provides partial protection against Plasmodium falciparum infection but determinants of protection and/or disease are unclear. Previously, anti-circumsporozoite protein (CSP) antibody titers and blood RNA signatures were associated
Ying Du, Ethan G. Thompson, Julius Muller, Joseph Valvo, Jackie Braun, Smitha Shankar, Robert A. van den Berg, Erik Jongert, Drew Dover, Jerald Sadoff, Jenny Hendriks, Malcolm J. Gardner, W. Ripley Ballou, Jason A. Regules, Robbert van der Most, Alan Aderem, Christian F. Ockenhouse, Adrian V. Hill, Ulrike Wille-Reece, Daniel E. Zak   +19 more
doaj   +1 more source

RTS,S/AS02 and the quest of the Holy Grail [PDF]

, 2002
High-profile programs under the WHO/Roll Back Malaria initiative, in addition to unravelling the human and malaria parasite genomes, have ensured that malaria vaccine research and development are enjoying an unprecedented boom. So far, the development of
Reithinger, R
core  

Neutropenia as an adverse event following vaccination : results from randomized clinical trials in healthy adults and systematic review [PDF]

, 2016
Background : In the context of early vaccine trials aimed at evaluating the safety profile of novel vaccines, abnormal haematological values, such as neutropenia, are often reported.
Aerssens, Annelies, Anemona, Alessandra, Bodinham, Caroline L, Groth, Nicola, Launay, Odile, Leroux-Roels, Geert, Lewis, David, Loulergue, Pierre, Muturi-Kioi, Vincent, Podda, Audino, Saul, Allan   +10 more
core   +4 more sources

RBD‐SD1 Nanoparticle Vaccines From DPP4‐Using Merbecoviruses Elicit a Cross‐Reactive Antibody Response but Limited Cross‐Protective Immunity

Biotechnology and Bioengineering, EarlyView.
SpyCatcher‐mi3 nanoparticles displaying RBD‐SD1 from MERS‐CoV, NL140422, and HKU4 elicited robust and cross‐reactive IgG responses in mice. Only MERS‐CoV RBD‐SD1 induced neutralizing antibodies against MERS‐CoV and protected human DPP4 mice from a MERS‐CoV challenge, indicating conserved serologic but limited cross‐neutralizing epitopes.
Peter J. Halfmann, Jeong Soo Lee, Tong Wang, Augustine Duffy, Janie E. Rogers, Natasha Chen, Elizabeth Frimpong, Carmen Rai, Yoshihiro Kawaoka, Ravi S. Kane   +9 more
wiley   +1 more source

Factors affecting home delivery in rural Tanzania [PDF]

, 2007
BACKGROUND\ud \ud Studies of factors affecting place of delivery have rarely considered the influence of gender roles and relations within the household.
Mrisho, M, Mshinda, H, Mushi, A, Obrist, B, Schellenberg, D, Schellenberg, JA, Tanner, M   +6 more
core   +2 more sources